Background Pemphigus vulgaris (PV) is a life-long IgG autoantibody-mediated blistering
Introduction
Pemphigus vulgaris (PV) is a life-long IgG autoantibodymediated blistering disease affecting the mucosal surfaces lined by the stratified epithelium (oral, nasal, and genital) and sometime also the skin. While the corticosteroid treatment is life saving, the high-dose and prolonged courses required for disease control are associated with significant adverse effects, including death. 1, 2 The hazardous side effects of conventional immunosuppressive therapy with high-dose systemic corticosteroids requiring prolonged and frequent hospitalizations make PV therapy very expensive 3 and necessitate meticulous care of a wide array of comorbid health conditions. 4 A systematic review and meta-analysis of randomized controlled trials evaluating the available evidence regarding efficacy and safety of interventions for PV concluded that despite their widespread use, it is not known if steroid-sparing agents are beneficial. 5 Although introduction of rituximab (RTX) provided for a favorable outcome, the high relapse rate, that is, up to 80%, 6 precludes successful use of RTX as a monotherapy. Intravenous immunoglobulin (IVIg) is being increasingly utilized as off-label therapy for a variety of autoimmune and inflammatory diseases, including PV and pemphigus foliaceus (PF) (reviewed in 
Patient characteristics
Medical records of a total of 117 PV and six PF patients (55 males and 68 females) aged 6-89 were analyzed retrospectively. All patients had active disease on the first visit, and all had been treated with prednisone and/or ISA in the past. Prior to initiation of treatment with the multidrug protocol, the mean duration of the disease was 2.7 years, ranging from 2 months to 16 years. Among these 123 patients, 32 PV and four PF patients had refractory disease, 79 PV and two PF patients had relapse, and six PV patients were previously untreated. All previously treated patients received prednisone together with con- 
Outcome measures
In the past, evaluations of therapeutic interventions in pemphigus were complicated by lack of generally accepted definitions and measurements for the clinical status of PV and PF patients.
Fortunately, this problem has been recently resolved. The endpoints in the present study were slightly modified from the international consensus outcome measures for pemphigus, 11 as follows: time to disease control (TDC) -lack of new lesions for a minimum of 2 weeks, and negative Nikolsky sign; 12 time to complete remission (TCR) -complete healing of erosions (with or without secondary skin changes) in the absence of new lesions and with negative Nikolsky sign; duration of complete remission on drugs (DCRon) until a relapse or end of therapy; duration of complete remission off drugs (DCRoff) until relapse or end of follow-up, as well as overall complete remission rate off all drugs, and rate of relapse (overall, and on and off drugs).
The relapse was defined as any increase from the previous PDAAI value in a particular patient lasting for at least 2 weeks.
During the treatment phase, all patients had follow-up visits at 4-6 week intervals on average and were required to come to 
Results

Clinical results in pemphigus patients treated with IVIg
As shown in Table 1 , the retrospective analysis of medical records of 123 pemphigus patients who had completed the These complications did not reoccur after IVIg treatment was resumed. All patients with a history of thromboembolic events received anticoagulant therapy.
The de novo adverse events developed after initiation of treatment that might not be related to IVIg per se included psychological abnormalities, such as agitation, depression and mood swings (9.8%), hypertension (11.4%), diabetes mellitus (8.1%), gastrointestinal distress (4.1%), and transaminitis (6.5%). Most of these complications apparently were caused by corticosteroids and/or ICDs, since they resolved after discontinuation of the offending drug. One PV patient (0.8%) who was treated with azathioprine died from pancytopenia and sepsis. No serious side effects and adverse reactions specific to RTX infusions were observed. In patients who developed transaminitis, a current ICD was replaced with another one and then, if no improvement of liver function tests, with RTX.
The effects of IVIg therapy with RTX or another ICD on circulating pemphigus autoantibody levels The IVIg treatment with an ICD or RTX produced similar results on the serum levels of pemphigus autoantibodies (Fig. 3) . (Fig. 3) . In contrast, approximately 8 and 28% of patients remained positive for anti-Dsg 1 and ant-Dsg 3 antibodies, respectively (Fig. 3) .
Discussion
The results of comprehensive treatment of our patients with PV and PF using the multidrug protocol that consisted of the initial loading dose of prednisone and prolonged administration of IVIg together with an ICD and mitochondrion-protecting drugs allowed to achieve three principal treatment objectives: (i) rapid control of pemphigus symptoms; (ii) stable disease remission; and (iii) overall safety of treatment. Although our therapeutic approach did not ultimately resolve the principal problem of pemphigus treatment because of remaining issues with adverse events from systemic corticosteroids and ICDs as well as a relatively long duration of treatment, it allowed to achieve a pro- . The rationale for concurrent administration of IVIg and an ICD was based on observations that, on one hand, depletion of pathogenic antibodies brings about a reciprocal increase in their serum levels, potentially leading to a flare of the disease, and, on the other hand, agents that suppress antibody synthesis can prevent such rebound and thus improve the effectiveness of IVIg therapy of pemphigus. 8, 34 The negative feedback mechanism limits the effectiveness of any antibody-eliminating therapy and helps explain sudden disease exacerbation within 2 weeks of IVIg therapy without ICD. 35 This same physiological mechanism, however, provides an opportunity to selectively suppress production of pathogenic antibodies, because only antibodies that have been depleted are resynthesized. The plasma cell producing depleted antibodies thus become a selective target for cytotoxic agents, because the ICDs such as azathioprine and mycophenolate mofetil were shown to be highly efficient against activated, compared to quiescent, lymphocytes. 36, 37 Hence, coadministration of IVIg and an ICD leads to "suicidal" proliferation of pathogenic antibody-producing cells. Indeed, it has been documented that pemphigus patients treated with such combined regimen had a greater decline in pathogenic autoantibodies, faster clinical improvement, and required a smaller cumulative dose of systemic corticosteroids. TDC in our patients was only 7-9 days, which apparently resulted from the additive keratinocyte-protecting actions of prednisone/methylprednisolone, minocycline (doxycycline), niacinamide (nicotinamide), and IVIg. The well-known rapid therapeutic effect of high doses of systemic corticosteroids [38] [39] [40] is mediated, in part, by their direct anti-acantholytic activity demonstrated in vitro using the active glucocorticosteroids hydrocortisone (i.e, synthetic cortisol) and methylprednisolone. [41] [42] [43] The inert prodrug prednisone has a lower risk for gastric damage compared to the active drug methylprednisolone 44 and, therefore, is the oral corticosteroid of choice for treating pemphigus patients. Prednisone undergoes its hepatic first pass activation by the enzyme 11b-hydroxysteroid dehydrogenase type 1.
45
Since all patients who were switched to methylprednisolone due to unresponsiveness to high doses of prednisone showed adequate treatment response, one may speculate that nonresponders to prednisone had a lower activity of this enzyme. Minocycline and niacinamide also exhibit direct anti-acantholytic effects owing to their mitochondrion-protecting properties. 46 The combination of niacinamide and minocycline has been empirically shown to be effective steroid-sparing agents in pemphigus (reviewed in 47 ). In addition to their well-known mechanism of pharmacological action, both drugs exhibit the mitochondrionprotecting effects by protecting the mitochondrial oxidative-phosphorylation function (niacinamide) and the outer membrane impermeability (minocycline), both of which are altered by antimitochondrial antibodies produced in PV patients. 48 The average TCR in our patients, 1.7 months, was comparable to that in other pemphigus patients treated by IVIg with or without RTX, which ranges from 1.7 to 2.1 months. 49, 50 In marked contrast, TCR in patients treated with RTX without IVIg and patients treated without either IVIg or RTX is much longer 2.3-5.8 months 51, 52 (reviewed in 53 ) and 4.3-5.9 months, 28, 54 respectively. This fact vividly demonstrated the benefit of including IVIg in the treatment protocol. Although we used the internationally agreed upon definition of TCR, 11 there may be some discordance with results reported by other groups.
In an in vitro model of therapeutic action of IVIg in pemphigus, normal human IgG has protected cultured keratinocytes from the PV IgG-induced cell death via apoptosis and oncosis, both of which can cause acantholysis. 55 Furthermore, IVIg can facilitate selective elimination of pathogenic antibodies from patients' blood. 56, 57 The most important outcome of the use of our multidrug treatment protocol was a relatively small relapse rate of 12%, which is much lower than that reported for pemphigus patients treated without IVIg (see Table 1 for details). In one of the previous studies, no patient was observed to have had a relapse of pemphigus from IVIg therapy. 31 For comparison, while 90-95% of patients treated with RTX experienced clinical remission, 16-80% had a relapse or required additional RTX (reviewed in 6, 28, [58] [59] [60] [61] [62] The concurrent administration of IVIg and RTX eliminates the major concern of using RTX in the treatment of pemphigus, such as the high incidence of systemic infections that can lead to fatal septicemia. 66, 67 As documented in this study and reported in literature, 49, 50 combination of RTX with IVIg brings RTX-related mortality down to zero.
A minor discrepancy between IIF and Dsg 1/3 ELISA results (Fig. 3) was not surprising. Herein, it should be clarified that in addition to anti-Dsg 1 and 3 antibodies, the pool of anti-keratinocyte antibodies produced in pemphigus patients includes a number of non-Dsg autoantibody species, which provides the basis for the multipathogenic explanation of pemphigus pathophysiology. 68 Both anti-Dsg and non-Dsg antibodies are pathogenic in a sense that they are elements of the multifactorial mechanism of keratinocyte damage in pemphigus (apoptoly- The most important outcome is improvement of the quality of life of the patients. As such, this regimen appears to be superior to the treatment modalities that do not include IVIg. A reasonable expectation that current complete remission in 100% of patients will extend indefinitely makes patients less apprehensive about possible flares and the need for additional therapy.
Indeed, the possibility that our patients develop a relapse in the future cannot be completely ruled out. However, since in the vast majority of patients pemphigus usually flares during the first 2 years, 70 the fact that by now 83 and 57 our patients have been in drug-free complete clinical remission for >2 and >5 years, respectively, gives a strong hope that they have been cured. A combination of IVIg and RTX may reverse autoimmunity. 78 The efficacy of the multidrug IVIg protocol does not depend on serological and clinical differences of individual patients, because a combination of IVIg with an ICD eliminates all kinds of pathogenic autoantibodies equally efficiently, and the mitochondrion-protecting drugs uniformly prevent keratinocyte apoptolysis triggered through various autoantibodyactivated signaling pathways. Future head-to-head prospective studies should ultimately clarify efficacies of different therapies in defined groups of patients.
